152 related articles for article (PubMed ID: 32995355)
1. Lentiviral Vector Production from a Stable Packaging Cell Line Using a Packed Bed Bioreactor.
Powers AD; Drury JE; Hoehamer CF; Lockey TD; Meagher MM
Mol Ther Methods Clin Dev; 2020 Dec; 19():1-13. PubMed ID: 32995355
[TBL] [Abstract][Full Text] [Related]
2. Development and Optimization of AAV hFIX Particles by Transient Transfection in an iCELLis(®) Fixed-Bed Bioreactor.
Powers AD; Piras BA; Clark RK; Lockey TD; Meagher MM
Hum Gene Ther Methods; 2016 Jun; 27(3):112-21. PubMed ID: 27229773
[TBL] [Abstract][Full Text] [Related]
3. Benchmarking of Scale-X Bioreactor System in Lentiviral and Adenoviral Vector Production.
Leinonen HM; Lepola S; Lipponen EM; Heikura T; Koponen T; Parker N; Ylä-Herttuala S; Lesch HP
Hum Gene Ther; 2020 Mar; 31(5-6):376-384. PubMed ID: 32075423
[TBL] [Abstract][Full Text] [Related]
4. Optimizing and developing a scalable, chemically defined, animal component-free lentiviral vector production process in a fixed-bed bioreactor.
Fiol CR; Collignon ML; Welsh J; Rafiq QA
Mol Ther Methods Clin Dev; 2023 Sep; 30():221-234. PubMed ID: 37528866
[TBL] [Abstract][Full Text] [Related]
5. Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor.
Valkama AJ; Leinonen HM; Lipponen EM; Turkki V; Malinen J; Heikura T; Ylä-Herttuala S; Lesch HP
Gene Ther; 2018 Jan; 25(1):39-46. PubMed ID: 29345252
[TBL] [Abstract][Full Text] [Related]
6. Process Development of Adenoviral Vector Production in Fixed Bed Bioreactor: From Bench to Commercial Scale.
Lesch HP; Heikkilä KM; Lipponen EM; Valonen P; Müller A; Räsänen E; Tuunanen T; Hassinen MM; Parker N; Karhinen M; Shaw R; Ylä-Herttuala S
Hum Gene Ther; 2015 Aug; 26(8):560-71. PubMed ID: 26176404
[TBL] [Abstract][Full Text] [Related]
7. Assessment of packed bed bioreactor systems in the production of viral vaccines.
Rajendran R; Lingala R; Vuppu SK; Bandi BO; Manickam E; Macherla SR; Dubois S; Havelange N; Maithal K
AMB Express; 2014; 4():25. PubMed ID: 24949260
[TBL] [Abstract][Full Text] [Related]
8. Continuous manufacturing of lentiviral vectors using a stable producer cell line in a fixed-bed bioreactor.
Stibbs DJ; Silva Couto P; Takeuchi Y; Rafiq QA; Jackson NB; Rayat ACME
Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101209. PubMed ID: 38435128
[TBL] [Abstract][Full Text] [Related]
9. Transient Lentiviral Vector Production Using a Packed-Bed Bioreactor System.
McCarron A; Donnelley M; McIntyre C; Parsons D
Hum Gene Ther Methods; 2019 Jun; 30(3):93-101. PubMed ID: 31084376
[TBL] [Abstract][Full Text] [Related]
10. Generation of stable suspension producer cell lines for serum-free lentivirus production.
Klimpel M; Terrao M; Bräuer M; Dersch H; Biserni M; Melo Do Nascimento L; Schwingal S; Vogel JE; Ferlemann C; Brandt T; Lal NI; Bridgeman K; Petzke A; McDwyer E; Lim JL; Oh S; Brumatti G; Garcia Minambres A; Otte E; Noll T; Pirzas V; Laux H
Biotechnol J; 2024 May; 19(5):e2400090. PubMed ID: 38719592
[TBL] [Abstract][Full Text] [Related]
11. Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-free Media.
Bauler M; Roberts JK; Wu CC; Fan B; Ferrara F; Yip BH; Diao S; Kim YI; Moore J; Zhou S; Wielgosz MM; Ryu B; Throm RE
Mol Ther Methods Clin Dev; 2020 Jun; 17():58-68. PubMed ID: 31890741
[TBL] [Abstract][Full Text] [Related]
12. Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor.
Wang X; Olszewska M; Qu J; Wasielewska T; Bartido S; Hermetet G; Sadelain M; Rivière I
J Immunother; 2015 Apr; 38(3):127-35. PubMed ID: 25751502
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Single-Use Fixed-Bed Bioreactors in Scalable Virus Production.
Lesch HP; Valonen P; Karhinen M
Biotechnol J; 2021 Jan; 16(1):e2000020. PubMed ID: 32971565
[TBL] [Abstract][Full Text] [Related]
14. Comparison of different bioreactor systems for the production of high titer retroviral vectors.
Merten OW; Cruz PE; Rochette C; Geny-Fiamma C; Bouquet C; Gonçalves D; Danos O; Carrondo MJ
Biotechnol Prog; 2001; 17(2):326-35. PubMed ID: 11312711
[TBL] [Abstract][Full Text] [Related]
15. Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines.
Manceur AP; Kim H; Misic V; Andreev N; Dorion-Thibaudeau J; Lanthier S; Bernier A; Tremblay S; Gélinas AM; Broussau S; Gilbert R; Ansorge S
Hum Gene Ther Methods; 2017 Dec; 28(6):330-339. PubMed ID: 28826344
[TBL] [Abstract][Full Text] [Related]
16. Insect cell entrapment, growth and recovering using a single-use fixed-bed bioreactor. Scaling up and recombinant protein production.
Ventini-Monteiro D; Dubois S; Astray RM; Castillo J; Pereira CA
J Biotechnol; 2015 Dec; 216():110-5. PubMed ID: 26481831
[TBL] [Abstract][Full Text] [Related]
17. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture.
Broussau S; Jabbour N; Lachapelle G; Durocher Y; Tom R; Transfiguracion J; Gilbert R; Massie B
Mol Ther; 2008 Mar; 16(3):500-7. PubMed ID: 18180776
[TBL] [Abstract][Full Text] [Related]
18. Challenges in the analysis of pharmaceutical lentiviral vector products by orthogonal and complementary physical (nano)particle characterization techniques.
Stadler D; Helbig C; Wuchner K; Frank J; Richter K; Hawe A; Menzen T
Eur J Pharm Biopharm; 2024 Jul; 200():114340. PubMed ID: 38797222
[TBL] [Abstract][Full Text] [Related]
19. Development of a perfusion process for continuous lentivirus production using stable suspension producer cell lines.
Klimpel M; Terrao M; Ching N; Climenti V; Noll T; Pirzas V; Laux H
Biotechnol Bioeng; 2023 Sep; 120(9):2622-2638. PubMed ID: 37148430
[TBL] [Abstract][Full Text] [Related]
20. Advancing a rapid, high throughput screening platform for optimization of lentivirus production.
Gopal S; Osborne AE; Hock L; Zemianek J; Fang K; Gee G; Ghosh R; McNally D; Cramer SM; Dordick JS
Biotechnol J; 2021 Oct; 16(10):e2000621. PubMed ID: 34260824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
